Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like From street to lab: Advancing controlled substance testing with handheld Raman and FTIR October 14, 2025 Study reveals ableism as a barrier to mental health care for disabled individuals December 11, 2024 Study reveals neurological effects of reused frying oils March 25, 2024
From street to lab: Advancing controlled substance testing with handheld Raman and FTIR October 14, 2025